Company intelligence / Profile preview

I Peace

Palo Alto, California, United Statesipeace.com ↗

Ownership: Private
Development stage: Phase 1

Overview

I Peace has developed an automated, scalable cGMP-compliant process to manufacture hundreds of discrete clinical-grade iPSC lines per year at reduced cost. Their technology enables both personal banking of youthful stem cells and supply to pharma/biotech partners globally. Hundreds of individuals have used their services in Japan; now expanding in the US. No proprietary therapeutic trial results reported—company acts as enabler/CDMO.

Therapeutic areas: Other
Modalities: Induced pluripotent stem cell derived therapyCell therapyGene therapyBiologic
Industry: Contract Manufacturing Organization

Drug pipeline

2 assets

iPSC-derived NK cells

Phase 1

Indications: Ovarian cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on I Peace.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on I Peace.

Explore the full profile